Navigation Links
A possible pathway for inhibiting liver and colon cancer is found
Date:7/8/2014

A group of scientists from Spain, the UK and the United States has revealed the structure of a protein complex involved in liver and colon cancers. Both of these types of cancer are of significant social and clinical relevance as in 2012 alone, liver cancer was responsible for the second highest mortality rate worldwide, with colon cancer appearing third in the list.

The international team from CIC bioGUNE, the University of Liverpool and the US research centre USC-UCLA has successfully unravelled the mechanism by which two proteins, MATα2 and MATβ, bind to each other, thereby promoting the reproduction of tumour cells in liver and colon cancers. The study was published in the latest issue of the open access journal IUCrJ published by the IUCr [Murray et al. (2014). IUCrJ 1, 240-249; doi: 10.1107/S2052252514012585]

This structural data discovery opens up additional research opportunities into drugs that can act on the binding of these proteins, thereby possibly inhibiting cancer cell growth.

As a result of this discovery, it is now known which part of their respective structures can be blocked to prevent these proteins from joining together. This is very important as when these proteins bind to each other, the production of a molecule known as SAMe, which plays a role in uncontrolled tumour cell growth, increases considerably. Though the relationship between SAMe and tumour growth has been known for some time, this molecule also has other important functions inside the cell that cannot be altered and there is currently no way of acting against it without affecting these other life-sustaining functions.

The good news is that MATα2 and MATβ are only overexpressed in adults with tumours therefore representing an excellent therapeutic target which could open the door to the creation of highly targeted drugs that act exclusively by blocking those regions that allow their mutual binding rather than attacking other regions of the body.

The CIC bioGUNE researcher Adriana Rojas, who led this study, mentioned during interview "Many years have passed since it was first understood which proteins produce SAMe and how the levels of this molecule affect cancer cell growth, and we have now shown that the complex between MATα2 and MATβ is a possible therapeutic target".

The research involved X-ray crystallography and solution X-ray scattering techniques utilizing some of Europe's most powerful X-ray synchrotron sources, ALBA in Spain and SOLEIL and DIAMOND in the UK.


'/>"/>

Contact: Dr. Jonathan Agbenyega
ja@iucr.org
44-124-434-2878
International Union of Crystallography
Source:Eurekalert  

Related medicine news :

1. Possible new cancer treatment identified
2. Study identifies possible protective blood factors against Type 2 diabetes
3. First study investigating possible link between sunscreen ingredient and endometriosis
4. Scientists identify possible drug target for acute pancreatitis
5. High-contrast, high-resolution CT scans now possible at reduced dose
6. US Drug Watchdog Dramatically Increases Their Efforts To Get All Recalled DePuy ASR Hip Implant Recipients Identified To The Best Possible Attorneys Before Time Runs Out
7. The US Drug Watchdog Now Urges Plaintiffs Law Firms Worldwide To Contact Them About A Possible International Effort To Help Victims Of Defective Drugs Or Medical Devices
8. Higher energies for laser-accelerated particles possible
9. Loss of protein SPDEF allows prostate cancer cells to gain foothold at possible sites of metastasis
10. Mutation in gene IDH a possible target for AML treatment
11. Mild HIV type slows development of AIDS and makes new preventive treatments possible
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A possible pathway for inhibiting liver and colon cancer is found
(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a locally ... business owners in North Central West Virginia, is embarking on a cooperative charity ... residents in the region. , The Stepping Stones organization offers a series of ...
(Date:6/22/2017)... ... 2017 , ... Plastic Surgery Associates is proud to report that founding surgeon, ... research and information firm, Castle Connolly, releases their list of the most notable and ... 3rd time that Dr. Canales has been recognized by Castle Connolly. , ...
(Date:6/22/2017)... ... June 22, 2017 , ... ... from the American Heart Association (AHA) to launch a Rheumatic Heart Disease Center, ... prevention and diagnosis of rheumatic heart disease (RHD) in high-risk, financially disadvantaged countries ...
(Date:6/22/2017)... , ... June 22, 2017 , ... ... announced today that it has received certification for ANSI/ASIS PSC.1-2012. The company’s work ... in environments where the rule of law has been degraded. The PSC.1 standard ...
(Date:6/20/2017)... ... June 20, 2017 , ... TwelveStone Health Partners, ... a Nashville-based private equity firm, has invested $3.35 million in the company. ... and Claritas Capital offers the smart money, speed to market and accountability we ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Endo International plc (NASDAQ: ENDP ) ... Joseph R. Goodwin , U.S. District Court Judge for ... , entered a case management order in MDL 2325, ... Litigation (the "MDL") that includes a provision requiring plaintiffs ... on specific causation within one hundred twenty (120) days ...
(Date:6/3/2017)... 2017  Eli Lilly and Company (NYSE: ... the Phase 3 MONARCH 2 study showed that ... in combination with fulvestrant, significantly improved progression-free survival ... women with hormone-receptor-positive (HR+), human epidermal growth factor ... relapsed or progressed after endocrine therapy (median PFS, ...
(Date:5/30/2017)... AVIV, Israel , May 30, 2017 ... stage pharmaceutical Company specializing in the development of ... will present a company overview at three upcoming ... The 7th Annual LD Micro Invitational: ... Date:                     ...
Breaking Medicine Technology: